Reversal of increased anxiety during benzodiazepine withdrawal: evidence for an anxiogenic endogenous ligand for the benzodiazepine receptor - PubMed (original) (raw)

Reversal of increased anxiety during benzodiazepine withdrawal: evidence for an anxiogenic endogenous ligand for the benzodiazepine receptor

H A Baldwin et al. Brain Res Bull. 1988 May.

Abstract

Rats were injected daily for 21 days with water or with chlordiazepoxide hydrochloride (10 mg/kg) and then tested in the elevated plus-maze 24-30 hr after the last of their chronic injections. At this time, rats withdrawn from chlordiazepoxide showed a significant decrease in the % of time spent on the open arms, compared with controls, thus indicating enhanced anxiety. The benzodiazepine antagonist, flumazenil (Ro 15-1788, 4 mg/kg, IP 20 min before test) significantly (p less than 0.01) reversed this withdrawal anxiety, and was without effect in the control group. The partial inverse agonist, FG 7142 (5 mg/kg IP 30 min before test) had no significant effect on the withdrawal anxiety. Possible mechanisms underlying the enhanced anxiety displayed by rats in withdrawal from chlordiazepoxide are discussed. It is concluded that a likely explanation is that chronic benzodiazepine treatment leads to an increased production and release of an endogenous ligand for the benzodiazepine receptor, with inverse agonist properties.

PubMed Disclaimer

Similar articles

• Chlordiazepoxide enhances the anxiogenic action of CGS 8216 in the social interaction test: evidence for benzodiazepine withdrawal?
  File SE, Pellow S. File SE, et al. Pharmacol Biochem Behav. 1985 Jul;23(1):33-6. doi: 10.1016/0091-3057(85)90126-1. Pharmacol Biochem Behav. 1985. PMID: 3929278
• Evidence that the increased anxiety detected in the elevated plus-maze during chlordiazepoxide withdrawal is not due to enhanced noradrenergic activity.
  Baldwin HA, Hitchcott PK, File SE. Baldwin HA, et al. Pharmacol Biochem Behav. 1989 Dec;34(4):931-3. doi: 10.1016/0091-3057(89)90298-0. Pharmacol Biochem Behav. 1989. PMID: 2623049
• Conflicting evidence regarding the efficacy of ondansetron in benzodiazepine withdrawal.
  Prather PL, Rezazadeh SM, Lane JD, Rowan GA, Hooper ML, Lytle DA, Emmett-Oglesby MW, Lal H. Prather PL, et al. J Pharmacol Exp Ther. 1993 Feb;264(2):622-30. J Pharmacol Exp Ther. 1993. PMID: 8094750
• The benzodiazepines: anxiolytic and withdrawal effects.
  Little HJ. Little HJ. Neuropeptides. 1991 Jul;19 Suppl:11-4. doi: 10.1016/0143-4179(91)90077-v. Neuropeptides. 1991. PMID: 1679209 Review.
• Pharmacological mechanisms of benzodiazepine withdrawal.
  Nutt DJ. Nutt DJ. J Psychiatr Res. 1990;24 Suppl 2:105-10. doi: 10.1016/0022-3956(90)90041-n. J Psychiatr Res. 1990. PMID: 1980689 Review.

Cited by

• Behavioral effects of flumazenil in the social conflict test in mice.
  Uhlírová L, Sustková-Fiserová M, Krsiak M. Uhlírová L, et al. Psychopharmacology (Berl). 2004 Jan;171(3):259-69. doi: 10.1007/s00213-003-1583-y. Epub 2003 Sep 5. Psychopharmacology (Berl). 2004. PMID: 12961060
• Progesterone withdrawal increases the alpha4 subunit of the GABA(A) receptor in male rats in association with anxiety and altered pharmacology - a comparison with female rats.
  Gulinello M, Gong QH, Smith SS. Gulinello M, et al. Neuropharmacology. 2002 Sep;43(4):701-14. doi: 10.1016/s0028-3908(02)00171-5. Neuropharmacology. 2002. PMID: 12367616 Free PMC article.
• Similar effects of ethanol and flumazenil on acquisition of a shuttle-box avoidance response during withdrawal from chronic ethanol treatment.
  Criswell HE, Breese GR. Criswell HE, et al. Br J Pharmacol. 1993 Oct;110(2):753-60. doi: 10.1111/j.1476-5381.1993.tb13876.x. Br J Pharmacol. 1993. PMID: 8242248 Free PMC article.
• Benzodiazepine/cholecystokinin interactions at functional CCK receptors in rat brain.
  Boden PR, Woodruff GN. Boden PR, et al. Br J Pharmacol. 1994 Jun;112(2):429-34. doi: 10.1111/j.1476-5381.1994.tb13090.x. Br J Pharmacol. 1994. PMID: 8075861 Free PMC article.
• The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze.
  Chopin P, Briley M. Chopin P, et al. Psychopharmacology (Berl). 1993;110(4):409-14. doi: 10.1007/BF02244646. Psychopharmacology (Berl). 1993. PMID: 7870910

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Medical

  • MedlinePlus Consumer Health Information
  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program